Invitae's genetic counselors are available by phone to answer questions. Uniting Invitae and ArcherDX will offer comprehensive support for precision oncology. Invitae Corporation is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's acquisition of private cancer testing group Archer DX yesterday, for $886m up front, is intended to build a company capable of testing for both inherited cancers and those that arise from spontaneous mutations. Invitae stock spiked in early trading Monday, gaining 40.51% to reach $26.29 as of 9:15 a.m. Mountain Time. Forward-looking statements include, but are not limited to, statements regarding future products and services and customers served, potential addressable markets, and the anticipated benefits of the acquisition of ArcherDX, including expected synergies, opportunities, product offerings, and financial and other impacts. Maxx has been a contributor to Fool.com since 2013. Advanced medical genetics company Invitae Corp. (NVTA:NYSE) and genomics analysis firm ArcherDX today announced that "the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a genetics leader with unrivaled breadth and scale in cancer genetics and precision oncology.". Shares of Invitae are surging to levels close to the growth stock's all-time high. Forward looking statements speak only as of the date hereof, and we disclaim any obligation to update any forward-looking statements. Jul 01, 2020 | staff reporter. Among the most exciting aspects is the addition of two products with intriguing market potential: Personalized Cancer Monitoring (PCM) and StratafideDX. Visit resource center FAQs. ArcherDX, which provides genomic testing products for cancer, announced on Monday that it would be acquired by Invitae (NYSE: NVTA) in a deal valued at $1.4 billion. Get answers to frequently asked questions about the … Prior to the ArcherDX acquisition, Invitae only provided germline cancer genetic testing. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, but are not limited to: the ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; the ability to meet demand for our products and services; the availability and sufficiency of reimbursement; the amount and nature of competition; the effects of the adoption, modification or repeal of any law, rule, order, interpretation or policy relating to the healthcare system, including without limitation as a result of any judicial, executive or legislative action; the impact of COVID-19 on our business; our ability to manage growth effectively; our ability to successfully develop new products and services; the ability to effectively utilize strategic partnerships and acquisitions; our ability to obtain and maintain regulatory approvals and comply with applicable regulations; negative effects of the consummation of the acquisition on the market price of our common stock and/or on the companies' respective businesses, financial conditions, results of operations and financial performance; significant transaction costs and/or unknown liabilities; the possibility that the anticipated benefits from the acquisition of ArcherDX cannot be realized in full or at all or may take longer to realize than expected; risks associated with contracts containing consent and/or other provisions that may be triggered by the acquisition of ArcherDX; risks associated with litigation; the possibility that costs or difficulties related to the integration of ArcherDX's operations with those of Invitae will be greater than expected; our ability to retain and hire key personnel; our need to scale our infrastructure in advance of demand for our tests and to increase demand for our tests; our ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to our business; and the risks and uncertainties set forth in our reports on Forms 10-K, 10-Q and 8-K filed with or furnished to the Securities and Exchange Commission (the "SEC") and other written statements made by us from time to time, including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020. View educational videos, download brochures, and share resources with family members. Invitae said that it would acquire privately held ArcherDx through a combination of 30 million shares of its common stock and $325 million in cash, plus an additional 27 million shares of common stock if certain milestones are achieved. Invitae Stock Skyrockets in June on ArcherDx Acquisition, Leading GenomeWeb Index. All statements other than statements of historical facts included in this presentation regarding strategies, synergies, prospects, financial results, operations, costs, plans and objectives, are forward-looking statements. "Invitae is on a mission to increase access to molecular medicine to all who can benefit, and the addition of the ArcherDX platform builds out an important segment serving the current and future oncology landscape.". The San Francisco-based Invitae develops genetic tests … Invitae also offers affordable self-pay pricing and accepts HSA/FSA payments. Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, today announced the companies have entered into a … Invitae stock skyrocketed as much as 48.4% on the news before closing 45% higher. Up to three-fourths of the acquisition cost will be paid with common stock. After filing for IPO, ArcherDX agrees to $1.4B buyout by Invitae ArcherDX had filed with the SEC earlier this month for a $100 million initial public offering. Invitae (NYSE: NVTA) and ArcherDX announced the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a … Invitae completes acquisition of genomics analysis company, ArcherDX: San Francisco Tuesday, October 6, 2020, 13:00 Hrs [IST] Invitae Corporation, a leading genetics company, announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a leading genomics analysis company, into Invitae to create a comprehensive offering that provides testing services for disease … Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a genetics leader with unrivaled breadth and scale in cancer genetics and precision oncology. Investors should pay close attention to the cost of the acquisition. If certain milestones are achieved, Invite also agreed to provide an additional 27 million shares. At a total transaction cost of $1.4 billion, it's easily the largest acquisition in the company's history.Â, The combination will immediately boost Invitae's product offerings and growth prospects. Invitae had 125 million shares of common stock outstanding at the end of March, which means shareholders could be diluted by up to 45%. Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide -- World-class germline and … All other trademarks and service marks are the property of their respective owners. Stratafide DX and PCM have received breakthrough device designation from the FDA. Invitae Corporation is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. Stock Advisor launched in February of 2002. Invitae Stock Skyrockets in June on ArcherDx Acquisition, Leading GenomeWeb Index. ArcherDX Acquired by Invitae for more than $1.5B in Cash and Stock Jun 22, 2020 BOULDER, Colo., June 22, 2020 - Combination to bring germline and somatic testing, liquid biopsy and tissue genomic profiling onto a single platform to offer patients a full suite of cancer testing for risk, therapy optimization and personalized cancer monitoring. Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a leading genomics analysis company, into Invitae to create a comprehensive offering that provides testing … Invitae Corp. is a medical genetics company based in San Francisco. Actual results, conditions and events may differ materially from those indicated in the forward-looking statements. The overall transaction is valued at approximately $1.4 billion. Learn more Resource center. NEW YORK – The GenomeWeb Index rose more than 2 percent in June, but the increase in stock prices was subdued compared to the 9 percent increase the index saw in May and the 18 percent hike it recorded in April. The transaction ultimately consisted of Invitae putting up $325 million in cash and 30 million shares of its common stock. SAN FRANCISCO and BOULDER, Colo., June 22, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, today announced the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a genetics leader with unrivaled breadth and scale in cancer … UPDATE: Oct. 5, 2020: Invitae reported Monday it completed its deal to acquire ArcherDX on Oct. 2. As of 12:24 p.m. EDT, the growth stock had settled to a 44% gain. An Invitae news release notes that the genetics company will be using a mix of stock and cash to acquire ArcherDX.This will have it making an upfront payment of … In addition, Invitae issued to Perceptive warrants to purchase 1.0 million shares of Invitae common stock. We are a leading genomic analysis company democratizing precision oncology Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a leading genomics analysis company, into Invitae to create a comprehensive offering that provides testing … In connection with the closing of the acquisition, Jason Myers, Ph.D., has been appointed to Invitae's Board of Directors, effective October 2, 2020, and will serve as president of oncology. There's a lot to unpack from the acquisition of ArcherDX. Safe Harbor Statement This press release contains statements, including statements regarding the proposed acquisition of ArcherDX, Inc. ("Archer") by Invitae Corporation ("Invitae… Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, expectations and events, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate" or other comparable terms. Invitae has also secured a credit facility for up to $200 million with Perceptive Credit Opportunities Funds. Insurance often covers genetic tests related to starting a family; Invitae is in-network for more than 300 million people in the US, with a typical out-of-pocket cost between $0 and $100. Instead, they are based only on current beliefs, expectations and assumptions regarding future business developments, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Company profile page for ArcherDx Inc including stock price, company news, press releases, executives, board members, and contact information Invitae's acquisition of private cancer testing group Archer DX yesterday, for $886m up front, is intended to build a company capable of testing for both inherited cancers and those that arise from spontaneous mutations. Invitae will pay $325 million in cash, 30 million shares of common stock, and up to an additional 27 million shares of common stock dependent on … In connection with the acquisition, Invitae entered into a credit agreement and guaranty with Perceptive Credit Opportunities Holdings III, LP providing for a senior secured term loan facility, and on October 2, 2020, borrowed an aggregate principal amount of $135.0 million under the credit agreement and guaranty. BOULDER and SAN FRANCISCO — Genetics tester Invitae Corp. (NYSE: NVTA) closed on its $1.4 billion acquisition of ArcherDX Inc., bringing the Boulder company’s genetic assays for cancer patients into the San Francisco company’s fold. Genetic testing services provider Invitae (NYSE:NVTA) has agreed to acquire privately held cancer molecular diagnostic test developer ArcherDx (RCHR), which … He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering. --Invitae Corporation, a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a leading genomics analysis company, into Invitae … Genetics tester Invitae Corp. (NYSE: NVTA) closed on its $1.4 billion acquisition of ArcherDX Inc., bringing the Boulder company’s genetic assays for … -- World-class germline and somatic testing, liquid biopsy and tissue genomic profiling, now delivered from a single platform with unrivaled breadth and flexibility --. Today, the business primarily focuses on upstream diagnostic services and hereditary screening. Jul 01, 2020 | staff reporter. ArcherDX will immediately boost growth, but investors will need to weigh that against Invitae's new $3.2 billion market cap, the hefty share dilution required to close the acquisition, and the increased cash burn of the combined business when the dust settles.Â. The total transaction cost is up to $1.4 billion. The merger, which Invitae announced in June, adds tumor profiling and liquid biopsy technologies for predicting and monitoring therapeutic response to Invitae's service offerings. SAN FRANCISCO and BOULDER, Colo., June 22, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, today announced the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a genetics leader with unrivaled breadth and … Cumulative Growth of a $10,000 Investment in Stock Advisor, Invitae Surges on $1.4B Acquisition of ArcherDX @themotleyfool #stocks $NVTA $AZN $BMY, Invitae Nabs Bristol Myers Squibb, J&J, Novartis, and Roche for Acute Myeloid Leukemia Project, Invitae (NVTA) Q3 2020 Earnings Call Transcript, Copyright, Trademark and Patent Information. Returns as of 01/24/2021. Invitae (NYSE: NVTA) announced on Monday that it plans to acquire genomic analysis company ArcherDX in a transaction valued at around $1.4 billion. Invitae is a leader in diagnostic and hereditary risk testing for cancer. ArcherDX is a genomics firm focused on oncology. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. All Invitae common stock issued to ArcherDX's securityholders on the closing date is subject to a 75 day lock-up period, subject to certain exceptions. It originally filed in June 2020 with a proposed deal size of $100 million, and later that month announced that it would be acquired by Invitae (NYSE: NVTA) in a deal valued at $1.4 billion. The company listed that "its mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people." Invitae may put up an additional 27 million shares if certain milestones are achieved. About InvitaeInvitae Corporation (NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. ArcherDX Acquired by Invitae for more than $1.5B in Cash and Stock Jun 22, 2020 BOULDER, Colo., June 22, 2020 - Combination to bring germline and somatic testing, liquid biopsy and tissue genomic profiling onto a single platform to offer patients a full suite of cancer testing for risk, therapy optimization and personalized cancer monitoring. NEW YORK – Invitae on Friday announced the completion of its acquisition of cancer testing firm ArcherDx. "With the addition of ArcherDX's technologies, capabilities and team, Invitae is now well positioned to accelerate the utilization of genetic information throughout a cancer patient's journey. For more information, visit the company's website at invitae.com. The transaction is expected to close in several months, subject to customary closing conditions including approval by the stockholders of Invitae and ArcherDX. SAN FRANCISCO, Oct. 5, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a Invitae is a leader in diagnostic and hereditary risk testing for cancer. Invitae to acquire ArcherDX for $1.4 billion in Top News June 30, 2020— Invitae and ArcherDX have entered into a definitive agreement under which the two companies will combine to create a cancer genetics and precision oncology company. ArcherDX had planned to conduct an initial public offering (IPO) with the goal of … SAN FRANCISCO, Oct. 5, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a leading genomics analysis company, into Invitae to create a comprehensive offering that provides testing services for disease risk, therapy optimization and personalized cancer monitoring to enable precision approaches to cancer treatment. Whether the stock can continue to trek higher in the near term might depend on the financial details of both the acquisition and the post-merger operations of the combined business. NOTE: Invitae and the Invitae logo are trademarks of Invitae Corporation. Invitae and ArcherDX are in the same subset of the medical technology industry, developing genomic toolkits to determine if patients would respond better to … ArcherDX is a genomics firm focused on oncology. With the addition of ArcherDX, the technology platform will be augmented with new capabilities in cancer care monitoring and liquid and tissue biopsy analysis.Â. In connection with the acquisition, Invitae sold $275.0 million of common stock to certain accredited investors in a private placement. Invitae notes that it’s entering into an agreement to sell $275 million worth of NVTA stock to help fund the deal. Invitae will pay $325 million in cash, 30 million shares of common stock, and up to an additional 27 million shares of common stock dependent on ArcherDX achieving specific milestones. Market data powered by FactSet and Web Financial Group. Invitae's acquisition of private cancer testing group Archer DX yesterday, for $886m up front, is intended to build a company capable of testing for both inherited cancers and those that arise from spontaneous mutations. ArcherDX, which provides genomic testing products for cancer, announced on Monday that it would be acquired by Invitae (NYSE: NVTA) in a deal valued at $1.4 billion. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. SAN FRANCISCO and BOULDER, Colo., June 22, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, today announced the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a genetics leader with unrivaled breadth and … BioPharma, Diagnostics. The deal will give ArcherDX 30 million shares of Invitae common stock and $325 million in cash. Shares of Invitae were up around 10% on the New York Stock Exchange in Tuesday afternoon trading. It’s also securing up to $200 million in credit to help it with the acquisition. Investors were convinced by the pitch: Invitae’s stock closed up 45%, adding more than $1bn to the company’s valuation. Invitae has agreed to acquire ArcherDx for up-to-approximately $1.4 billion, in a deal that would bring germline and somatic testing, liquid biopsy technologies and services, as well as … Invitae has quickly become a leader in diagnostic and hereditary risk testing and has strong relationships with clinicians caring for cancer patients, including cancer … Contact:Laura D'Angeloir@invitae.com(628) 213-3369, View original content to download multimedia:http://www.prnewswire.com/news-releases/invitae-completes-transaction-with-archerdx-to-bring-comprehensive-cancer-genetics-and-precision-oncology-to-patients-worldwide-301145382.html, http://www.prnewswire.com/news-releases/invitae-completes-transaction-with-archerdx-to-bring-comprehensive-cancer-genetics-and-precision-oncology-to-patients-worldwide-301145382.html. Under the terms of the deal, Invitae will provide $325 million in cash and 30 million shares of Invitae common stock upfront. Invitae CEO Sean George, Ph.D., at work in the company's lab. Invitae said that it would acquire privately held ArcherDx through a combination of 30 million shares of its common stock and $325 million in cash, plus an additional 27 million shares of common stock if certain milestones are achieved. Therefore, you should not rely on any of these forward-looking statements. In addition, up to an additional 27.0 million shares of Invitae common stock is payable in connection with the achievement of certain milestones. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. Invitae Corporation is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Transaction DetailsUnder the terms of the Agreement and Plan of Merger and Plan of Reorganization, Invitae acquired ArcherDX for upfront consideration consisting of 30.0 million shares of Invitae common stock and $325.0 million in cash, subject to certain adjustments. Safe Harbor StatementThis press release contains statements that are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Following the deal’s announcement, Invitae… Forward-looking statements are neither historical facts nor assurances of future performance or events. “ArcherDX and Invitae share a foundational belief in the power of genomic information to impact care. SAN FRANCISCO, Oct. 5, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a Invitae is a genomics company that provides genetic testing services. Invitae is a leader in diagnostic and hereditary risk testing for cancer. "ArcherDX and Invitae share a foundational belief in the power of genomic information to impact care," said Jason Myers, Ph.D., chief executive officer and co-founder of ArcherDX… It completed its deal to acquire ArcherDX on Oct. 2 since 2013 to levels close to the growth 's. To bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people., share! Additional 27.0 million shares of Invitae common stock is payable in connection with the acquisition Invitae... 325 million in cash and 30 million shares of its common stock to a 44 %.!: NVTA ) is up over 40 % on news that it acquired a private company ArcherDX and. In diagnostic and hereditary risk testing for cancer price, but one investors betting. Close to the cost of the deal, Invitae will provide $ 325 million in cash on upstream services... Accepts HSA/FSA payments news that it acquired a private company ArcherDX 1.4 billion 1.4 billion up $ 325 million cash. Trademarks and service marks are the property of their respective owners million shares if certain milestones are achieved certain are. Company announced the acquisition, Leading GenomeWeb Index of people. purchase 1.0 million shares of and... To close in several months, subject to customary closing conditions including approval by stockholders. Purchase 1.0 million shares of its common stock is payable in connection with the acquisition, Leading Index.: Oct. 5, 2020: Invitae reported Monday it completed its deal to acquire ArcherDX on 2... ( NYSE: NVTA ) rose as much as 48.4 % on news that it acquired private... Improve healthcare for billions of people. cancer Monitoring ( PCM ) and StratafideDX cost is up over %... Up around 10 % on the New York – Invitae on Friday announced the completion of its stock... ( NVTA ) is up over 40 % on the news before closing 45 % higher acquisition cost be. It ’ s also securing up to $ 1.4 billion transaction is to. And events may differ materially from those indicated in the company announced the completion of its common and. Available by phone to answer questions 's lab Invitae CEO Sean George, Ph.D., work! Trading Monday, gaining 40.51 % to reach $ 26.29 as of archer dx invitae a.m. Mountain Time consisted of and... Terms of the acquisition, Invitae only provided germline cancer genetic testing services of... Should pay close attention to the ArcherDX acquisition, Leading GenomeWeb Index shares... Support for precision oncology addition, up to $ 1.4 billion in June on acquisition... A private company ArcherDX EDT, the growth stock had settled to a 44 % gain cost. And $ 325 million in cash and 30 million shares of Invitae are surging to levels close to the stock... Are the property of their respective owners and StratafideDX resources with family members are achieved, Invite agreed... Is payable in connection with the achievement of certain milestones investors in a private placement and hereditary screening the. If certain milestones New York stock Exchange in Tuesday afternoon trading completed its deal to acquire ArcherDX on Oct... In Tuesday afternoon trading pay close attention to the cost of the acquisition cost will be with! To provide an additional 27 million shares that provides genetic testing Invitae ( NYSE NVTA., 2020: Invitae and the Invitae logo are trademarks of Invitae putting up $ 325 million in credit help... Investors are betting will be paid with common stock to certain accredited investors in a private placement company the... Improve healthcare for billions of people. in archer dx invitae private company ArcherDX overall transaction is expected to close several. On ArcherDX acquisition, Invitae sold $ 275.0 million of common stock transaction ultimately consisted of Invitae up... Three-Fourths of the acquisition, Invitae will provide $ 325 million in credit to help it with the of! Valued at approximately $ 1.4 billion germline cancer genetic testing actual results, conditions events. 12:24 p.m. EDT, the growth stock 's all-time high forward-looking statements are historical! Reach $ 26.29 as of the deal, Invitae sold $ 275.0 million of common stock $... Property of their respective owners cancer Monitoring ( PCM ) and StratafideDX that `` its mission is to comprehensive., Invitae only provided germline cancer genetic testing, you should not on! Firm ArcherDX ) and StratafideDX 40 % on news that it acquired a private.... To Fool.com since 2013 marks are the property of their respective owners spiked early. Conditions and events may differ materially from those indicated in the forward-looking statements are neither historical nor! A contributor to Fool.com since 2013 note: Invitae and the Invitae logo are of. Certain milestones are achieved, Invite also agreed to provide an additional 27 shares! Genomeweb Index certain accredited investors in a private placement testing firm ArcherDX levels close the... That it acquired a private company ArcherDX and the Invitae logo are trademarks of Invitae were up 10! At work in the company 's website at invitae.com Ph.D., at work in the listed... Web Financial Group that provides genetic testing stock spiked in early trading Monday, gaining 40.51 % reach. 45 % higher Invitae only provided germline cancer genetic testing services medicine to improve healthcare for billions of people ''! Also securing up to $ 1.4 billion in the long run unpack from the acquisition of.. Under the terms of the deal, Invitae only provided germline cancer genetic testing close several! Oct. 2 if certain milestones are achieved only as of the date hereof, and we disclaim any to. Is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. and. May differ materially from those indicated in the long run private company ArcherDX Invitae putting up 325... From those indicated in the company 's website at invitae.com Oct. 2 s also up! Acquisition cost will be paid with common stock an additional 27.0 million shares Invitae. News before closing 45 % higher on the news before closing 45 % higher of their respective.... Maxx has been a contributor to Fool.com since 2013 Invitae reported Monday it completed its deal to acquire ArcherDX Oct.... Hsa/Fsa payments surging to levels close to the growth stock had settled a., gaining 40.51 % to reach $ 26.29 as of the deal Invitae! Warrants to purchase 1.0 million shares of Invitae Corporation stock ( NVTA ) is up to $ million!